成大生物：流感病毒裂解疫苗(高剂量)获得药物临床试验批准通知书

Core Viewpoint - Chengda Bio (688739.SH) has received approval from the National Medical Products Administration for clinical trials of its high-dose influenza virus split vaccine [1] Group 1: Company Developments - Chengda Bio's wholly-owned subsidiary, Chengda Bio (Benxi) Co., Ltd., has been granted a Clinical Trial Approval Notice for the high-dose influenza virus split vaccine [1] - The vaccine is developed using the influenza virus strains recommended by the World Health Organization (WHO) and is designed to contain four times the effective components of a conventional dose [1]